Zamzam Al-Habsi1, Huda Al-Noumani2, Iman Al Hashmi3. 1. Sultan Qaboos University Hospital, Al Seeb, Oman. 2. Sultan Qaboos University College of Nursing, Al Seeb, Oman. hudasn@squ.edu.om. 3. Sultan Qaboos University College of Nursing, Al Seeb, Oman.
Abstract
PURPOSE: This study aimed to examine the difference in HRQoL by participants' characteristics and to investigate the determinants of health-related quality of life HRQoL among Omani hospitalized patients with cancer. METHODS: This cross-sectional study was conducted in two oncology centers in Oman. Omani hospitalized patients with breast, thyroid, colorectal, stomach, and prostate cancer were recruited using convenience sampling. Participants completed Arabic versions of Pittsburgh Sleep Quality Index to measure sleep quality, Brief Fatigue Inventory scales to measure fatigue, and Functional Assessment of Cancer Therapy to measure HRQoL. Descriptive and inferential statistics were performed. T-test, ANOVA, and multiple linear regression analysis were utilized to determine predictors of HRQOL. RESULTS: In total, 275 participants were recruited (Meanage = 52 years). About 64% of the participates reported poor sleep and 18.5% reported severe cancer-related fatigue. Younger patients who had good sleep quality and less cancer-related fatigue and had prostate and thyroid cancer demonstrated better HRQoL [F (5, 269) = 26.26, p < 0.000]. The model explained 33% of the variances in the HRQoL (R2 = .328). CONCLUSIONS: This study highlights the impact of age, cancer type, sleep quality, and cancer-related fatigue on the HRQoL in hospitalized patients with cancer. Thus, sleep quality and cancer-related fatigue should be assessed routinely during the hospitalization of oncology patients with unique attention to patients' age and cancer type.
PURPOSE: This study aimed to examine the difference in HRQoL by participants' characteristics and to investigate the determinants of health-related quality of life HRQoL among Omani hospitalized patients with cancer. METHODS: This cross-sectional study was conducted in two oncology centers in Oman. Omani hospitalized patients with breast, thyroid, colorectal, stomach, and prostate cancer were recruited using convenience sampling. Participants completed Arabic versions of Pittsburgh Sleep Quality Index to measure sleep quality, Brief Fatigue Inventory scales to measure fatigue, and Functional Assessment of Cancer Therapy to measure HRQoL. Descriptive and inferential statistics were performed. T-test, ANOVA, and multiple linear regression analysis were utilized to determine predictors of HRQOL. RESULTS: In total, 275 participants were recruited (Meanage = 52 years). About 64% of the participates reported poor sleep and 18.5% reported severe cancer-related fatigue. Younger patients who had good sleep quality and less cancer-related fatigue and had prostate and thyroid cancer demonstrated better HRQoL [F (5, 269) = 26.26, p < 0.000]. The model explained 33% of the variances in the HRQoL (R2 = .328). CONCLUSIONS: This study highlights the impact of age, cancer type, sleep quality, and cancer-related fatigue on the HRQoL in hospitalized patients with cancer. Thus, sleep quality and cancer-related fatigue should be assessed routinely during the hospitalization of oncology patients with unique attention to patients' age and cancer type.
Authors: Christina Fitzmaurice; Daniel Dicker; Amanda Pain; Hannah Hamavid; Maziar Moradi-Lakeh; Michael F MacIntyre; Christine Allen; Gillian Hansen; Rachel Woodbrook; Charles Wolfe; Randah R Hamadeh; Ami Moore; Andrea Werdecker; Bradford D Gessner; Braden Te Ao; Brian McMahon; Chante Karimkhani; Chuanhua Yu; Graham S Cooke; David C Schwebel; David O Carpenter; David M Pereira; Denis Nash; Dhruv S Kazi; Diego De Leo; Dietrich Plass; Kingsley N Ukwaja; George D Thurston; Kim Yun Jin; Edgar P Simard; Edward Mills; Eun-Kee Park; Ferrán Catalá-López; Gabrielle deVeber; Carolyn Gotay; Gulfaraz Khan; H Dean Hosgood; Itamar S Santos; Janet L Leasher; Jasvinder Singh; James Leigh; Jost B Jonas; Jost Jonas; Juan Sanabria; Justin Beardsley; Kathryn H Jacobsen; Ken Takahashi; Richard C Franklin; Luca Ronfani; Marcella Montico; Luigi Naldi; Marcello Tonelli; Johanna Geleijnse; Max Petzold; Mark G Shrime; Mustafa Younis; Naohiro Yonemoto; Nicholas Breitborde; Paul Yip; Farshad Pourmalek; Paulo A Lotufo; Alireza Esteghamati; Graeme J Hankey; Raghib Ali; Raimundas Lunevicius; Reza Malekzadeh; Robert Dellavalle; Robert Weintraub; Robyn Lucas; Roderick Hay; David Rojas-Rueda; Ronny Westerman; Sadaf G Sepanlou; Sandra Nolte; Scott Patten; Scott Weichenthal; Semaw Ferede Abera; Seyed-Mohammad Fereshtehnejad; Ivy Shiue; Tim Driscoll; Tommi Vasankari; Ubai Alsharif; Vafa Rahimi-Movaghar; Vasiliy V Vlassov; W S Marcenes; Wubegzier Mekonnen; Yohannes Adama Melaku; Yuichiro Yano; Al Artaman; Ismael Campos; Jennifer MacLachlan; Ulrich Mueller; Daniel Kim; Matias Trillini; Babak Eshrati; Hywel C Williams; Kenji Shibuya; Rakhi Dandona; Kinnari Murthy; Benjamin Cowie; Azmeraw T Amare; Carl Abelardo Antonio; Carlos Castañeda-Orjuela; Coen H van Gool; Francesco Violante; In-Hwan Oh; Kedede Deribe; Kjetil Soreide; Luke Knibbs; Maia Kereselidze; Mark Green; Rosario Cardenas; Nobhojit Roy; Taavi Tillmann; Taavi Tillman; Yongmei Li; Hans Krueger; Lorenzo Monasta; Subhojit Dey; Sara Sheikhbahaei; Nima Hafezi-Nejad; G Anil Kumar; Chandrashekhar T Sreeramareddy; Lalit Dandona; Haidong Wang; Stein Emil Vollset; Ali Mokdad; Joshua A Salomon; Rafael Lozano; Theo Vos; Mohammad Forouzanfar; Alan Lopez; Christopher Murray; Mohsen Naghavi Journal: JAMA Oncol Date: 2015-07 Impact factor: 31.777